|

EXS74539 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: REC-4539

Pipeline

Phase 1: 1

Top Sponsors

  • Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1

Indications

  • Renal Carcinoma (Clear and Non-clear Cell)1
  • Small Cell Carcinomas of Non-lung Origin1
  • Liver Disease1
  • High Grade Neuroendocrine Cancer1
  • Hepatic Cancer1

Fort Worth, Texas1 trial

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

START Dallas

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.